Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.
Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...
such as J&J's own Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), and Sun Pharma’s Ilumya (tildrakizumab). FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg ...
Effective from 1 April 2025, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S and Totalkredit A/S will be adjusted. The new coupon rates will apply from 1 April 2025 to 30 ...
The cost of Ocrevus can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Ocrevus. As with all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback